Beam Therapeutics Inc. (BEAM): Cash & Equivalents
$294.94M
As of 2025-12-31
$219.82M
As of 2026-06-30
+8.2%
3-year compound annual growth
+12.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $294.94M | +4.6% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $281.97M | -35.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $435.89M | +87.3% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $232.77M | -58.4% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $559.99M | +245.3% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $162.17M | +335.7% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $37.22M | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $294.94M | +4.6% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $167.20M | -70.2% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗